Janux Therapeutics, Inc. Gain (Loss) on Disposition of Assets
Janux Therapeutics, Inc. (JANX) reported Gain (Loss) on Disposition of Assets of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-10.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnDispositionOfAssets1 · last filed 2023-03-10
- Janux Therapeutics, Inc. gain (loss) on disposition of assets for the quarter ending 2022-12-31 was $0.00.
- Janux Therapeutics, Inc. gain (loss) on disposition of assets for the quarter ending 2022-09-30 was $0.00.
- Janux Therapeutics, Inc. gain (loss) on disposition of assets for the quarter ending 2021-12-31 was $0.00.
- Janux Therapeutics, Inc. gain (loss) on disposition of assets for the quarter ending 2021-09-30 was $0.00.
- Janux Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2022 was $0.00.
- Janux Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2021 was -$3.00K.
- Janux Therapeutics, Inc. gain (loss) on disposition of assets for fiscal 2020 was $0.00.
| Period end | Gain (Loss) on Disposition of Assets 3 month | Gain (Loss) on Disposition of Assets 6 month | Gain (Loss) on Disposition of Assets 9 month | Gain (Loss) on Disposition of Assets 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-10 | $0.00 10-K · filed 2023-03-10 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $0.00 derived: sum of 2 quarters · filed 2023-03-10 | -$3.00K 10-K · filed 2023-03-10 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$3.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | -$3.00K 10-Q · filed 2022-08-09 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |